BioXcel Therapeutics Inc. (BTAI)
NASDAQ: BTAI
· Real-Time Price · USD
5.60
0.12 (2.19%)
At close: Aug 18, 2025, 2:50 PM
BioXcel Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -19.19M | -7.25M | -10.86M | -13.65M | -8.3M | -26.79M | -22.26M | -50.49M | -53.52M | -52.8M | -54.81M | -41.81M | -37.67M | -31.47M | -26.13M | -26.81M | -27.62M | -26.38M |
Depreciation & Amortization | 75K | 76K | 77K | 77K | 77K | 78K | 78K | 79K | 81K | 80K | 81K | 85K | 84K | 77K | 76K | 77K | 79K | 65K |
Stock-Based Compensation | 1.56M | 180K | -199K | 1.86M | 1.06M | 3.43M | 3.6M | 4.01M | 6.12M | 4.88M | 4.55M | 4.48M | 4.48M | 3.83M | 2.24M | 4.88M | 6.77M | 5.57M |
Other Working Capital | -28K | 518K | -943K | -1.63M | -584K | 199K | 2.43M | 1.16M | 2.51M | 4.66M | 1.68M | 5.03M | -3.6M | -3.48M | 1.84M | -644K | -1.77M | 703K |
Other Non-Cash Items | 2.58M | -3.46M | -273K | -3.31M | -10.59M | 1.3M | 16.3M | 789K | 761K | 962K | 1.2M | 557K | 321K | 5.34M | -3.88M | 46K | 6.93M | 5.7M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -15.38M | 1K | -546K | n/a | n/a | n/a | n/a | n/a | 3.88M | n/a | n/a | n/a |
Change in Working Capital | 2.4M | -1.58M | -3.56M | -1.32M | -5.42M | 4.27M | -9.2M | 8.02M | 8.89M | -5.48M | 10.34M | 5.5M | -320K | -4.84M | 3.88M | 1.6M | -1.61M | 1.11M |
Operating Cash Flow | -12.57M | -12.04M | -14.81M | -16.34M | -23.17M | -17.71M | -26.86M | -37.58M | -38.21M | -52.35M | -38.64M | -31.19M | -33.1M | -32.41M | -19.93M | -20.2M | -22.38M | -19.64M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -20K | n/a | -0.14 | n/a | -19K | -120K | -12K | -17K | -100K | -316K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -20K | n/a | -0.14 | n/a | -19K | -120K | -12K | -17K | -100K | -316K |
Debt Repayment | n/a | n/a | -2.5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 30M | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | -1K | 39.28M | n/a | -8K | -117K | -252K | n/a | 250K | -508K | 50K | 48K | 66.14M | n/a | n/a | 105K | 497K | 852K |
Financial Cash Flow | 137K | 13.2M | 4.28M | 454K | 5.3M | 26.63M | 2.12M | n/a | 250K | 24.15M | 50K | 30.05M | 66.14M | n/a | n/a | 71K | 101.52M | 852K |
Net Cash Flow | -12.44M | 1.16M | -10.53M | -15.88M | -17.87M | 8.92M | -24.74M | -37.58M | -37.98M | -28.2M | -38.59M | -1.14M | 33.02M | -32.53M | -19.94M | -20.14M | 79.04M | -19.1M |
Free Cash Flow | -12.57M | -12.04M | -14.81M | -16.34M | -23.17M | -17.71M | -26.86M | -37.58M | -38.23M | -52.35M | -38.64M | -31.19M | -33.12M | -32.53M | -19.94M | -20.22M | -22.48M | -19.96M |